TCM
AKRO

Tekla Capital Management’s Akero Therapeutics AKRO Stock Holding History

Tekla Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$2.87M Buy
+61,497
New +$2.82M 0.11% 101

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Tekla Capital Management's AKRO Position: Q2 2023 in Review

Tekla Capital Management opened a new position in Akero Therapeutics (AKRO) in Q2 2023: 61,497 shares worth $2.87M. The stake represents 0.11% of the portfolio and ranks #101 among its holdings.

157 funds tracked by Wall St. Rank hold AKRO as of Q2 2023.

  • Tekla Capital Management held 61,497 shares of Akero Therapeutics worth $2.87M as of Q2 2023.
  • Akero Therapeutics was a new Tekla Capital Management position in Q2 2023.
  • Akero Therapeutics made up 0.11% of Tekla Capital Management's portfolio in Q2 2023, its #101 holding.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.